Ionis Pharmaceuticals INC Form 4 insider transactions

Patrick R. O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals, acquired 246 shares of common stock through the company's employee stock purchase plan on August 30, 2024.

Ionis Pharmaceuticals CEO Brett P. Monia reports the acquisition of 140 shares of common stock through the company's Employee Stock Purchase Plan.

EVP Richard S. Geary of Ionis Pharmaceuticals reports purchasing common stock under the company's employee stock purchase plan.

Brian Birchler, EVP at Ionis Pharmaceuticals, reports the acquisition of 12 common stock shares through the company's employee stock purchase plan at a price of $38.641 per share.

EVP, Chief Scientific Officer of Ionis Pharmaceuticals, C. Frank Bennett, reports acquiring 177 shares of common stock through the company's employee stock purchase plan.

Richard S. Geary, EVP and Chief Development Officer of Ionis Pharmaceuticals, amends a previous Form 4 filing to correct the number of shares sold and beneficially owned.

Elizabeth Hougen, EVP, Finance & CFO of Ionis Pharmaceuticals, amends a previous Form 4 filing to correct the number of shares sold on February 2, 2024.

Patrick R. O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals, amends a previous SEC Form 4 filing to correct the number of shares sold on February 2, 2024.

Eugene Schneider, EVP, Chf Clinical Develop Ofcr of Ionis Pharmaceuticals, amends a previous SEC Form 4 filing to correct the number of shares sold on February 2, 2024.

Eric Swayze, EVP of Research at Ionis Pharmaceuticals, amends a previous Form 4 filing to correct the number of shares sold on February 2, 2024.

Brett Monia, CEO of Ionis Pharmaceuticals, amended a previous Form 4 filing to accurately reflect the number of shares sold on February 2, 2024.

Brett Monia, CEO of Ionis Pharmaceuticals, amended a previous Form 4 filing to accurately reflect the number of shares sold on February 2, 2024.

Onaiza Cadoret-Manier, EVP at Ionis Pharmaceuticals, amends a previous SEC filing to correct the number of shares sold and beneficially owned.

C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals, amended a previous Form 4 filing to correct the number of shares sold on February 2, 2024.

EVP and Chief Development Officer of Ionis Pharmaceuticals, Richard S. Geary, executed sales of common stock under a pre-arranged Rule 10b5-1 trading plan.

Richard S. Geary, EVP and Chief Development Officer of Ionis Pharmaceuticals, sold 2,430 shares of common stock at $48 per share on August 5, 2024, under a pre-arranged 10b5-1 trading plan.

Director Joseph H. Wender reports the vesting of restricted stock units into Ionis Pharmaceuticals common stock.

Director B. Lynne Parshall reports the vesting of restricted stock units into 4,677 shares of Ionis Pharmaceuticals common stock.

Director Joseph Loscalzo reports the vesting of restricted stock units into Ionis Pharmaceuticals common stock.

Director Joseph Klein III exercised stock options and sold shares of Ionis Pharmaceuticals (IONS) on July 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Joan E. Herman acquired 4,677 shares of Ionis Pharmaceuticals common stock on July 15, 2024, through the vesting of restricted stock units.

Director Allene M. Diaz of Ionis Pharmaceuticals executed stock sales and RSU vesting, resulting in changes to her beneficial ownership.

Director Spencer R. Berthelsen reports the vesting of restricted stock units into Ionis Pharmaceuticals common stock.

Director Michael Yang reports acquisition of restricted stock units in Ionis Pharmaceuticals, adjusted to comply with director compensation policy.

Director Michael J. Yang received stock options for 10,111 shares of Ionis Pharmaceuticals common stock on July 1, 2024, as part of the company's Non-Employee Director Compensation Policy.

Director Joseph H. Wender received stock options and restricted stock units from Ionis Pharmaceuticals on July 1, 2024, as part of the company's non-employee director compensation policy.

Director B. Lynne Parshall reports receiving stock options and restricted stock units from Ionis Pharmaceuticals as part of their non-employee director compensation.

Director Joseph Loscalzo receives stock options and restricted stock units from Ionis Pharmaceuticals as part of the company's non-employee director compensation policy.

Director Joseph Klein III received stock options and restricted stock units from Ionis Pharmaceuticals on July 1, 2024, as part of the company's non-employee director compensation policy.

Director Joan E. Herman received stock options and restricted stock units from Ionis Pharmaceuticals on July 1, 2024, as part of the company's non-employee director compensation policy.